Mitochondrial Targeting of Metformin Enhances Its Activity against Pancreatic Cancer

Area of Science:

• Oncology
• Pharmacology
• Mitochondrial Biology

Background:

• Pancreatic cancer is a challenging disease with limited treatment options.
• Metformin, a diabetes drug, shows low efficacy against pancreatic cancer.
• Targeting metformin to mitochondria may improve its anti-cancer activity.

Purpose of the Study:

• To develop and evaluate mitochondrially targeted metformin (MitoMet) for pancreatic cancer.
• To investigate MitoMet's efficacy and molecular target in pancreatic cancer cells and models.

Main Methods:

• Synthesizing MitoMet by conjugating metformin with a triphenylphosphonium group.
• Assessing cytotoxicity of MitoMet against pancreatic cancer cell lines.
• Evaluating mitochondrial complex I (CI) as the molecular target using respiration assays and molecular modeling.
• Testing MitoMet efficacy in preclinical pancreatic cancer mouse models.

Main Results:

• MitoMet demonstrated 3-4 orders of magnitude greater potency than metformin against pancreatic cancer cells.
• Respiration analysis and molecular modeling confirmed CI as MitoMet's molecular target.
• MitoMet effectively suppressed tumor growth in three distinct mouse models of pancreatic cancer.

Conclusions:

• MitoMet is a potent, mitochondrially targeted derivative of metformin.
• MitoMet shows significant preclinical efficacy against pancreatic cancer.
• MitoMet represents a promising novel therapeutic strategy for pancreatic cancer patients.